>

Galapagos Stock Profile

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:4em;padding-top: 25px;;'>GA</div>

Performance

Odds of Distress

Analyze Filter   Earnings Report: April 24, 2020
Equity ratings for Galapagos NV are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 30, 2019 and ending today February 28, 2020. Click here to learn more.

Galapagos Profile

Next earnings report is expected on April 24, 2020. Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. more on Galapagos
Galapagos Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Galapagos NV SEC Filings
Galapagos SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameGalapagos NV
CEOOnno StolpeView All
Thematic Classification
Currently Active Investing Idea
  Biotech
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Galapagos NV
Piotroski F Score
Academic score to determine the current strength of Galapagos NV financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
Galapagos NV ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Debt to Equity Ratio
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Profitability
Few selected profitability drivers of Galapagos representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
EBITDA Margin
Gross Margin
Profit Margin
Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 918 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 11.04 B. Galapagos NV conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 61.95 M outstanding shares of which 1.24 M shares are currently shorted by private and institutional investors with about 9.18 trading days to cover. N/A currently holds about 1.57 B in cash with (181.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 28.83.
Check Galapagos Probability Of Bankruptcy

Ownership Allocation (%)

Galapagos Stock Price Odds Analysis

Odds Down 238.08HorizonTargetOdds Up 238.08
77.09%30 days 238.08 22.79%
Based on normal probability distribution, the odds of Galapagos to move above current price in 30 days from now is about 22.79 (This Galapagos NV probability density function shows the probability of Galapagos Stock to fall within a particular range of prices over 30 days) .

Galapagos Stock Top Holders

Galapagos NV Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Galapagos Stock Against Markets

Did you try this?

Run Money Flow Index Now

   

Money Flow Index

Determine momentum by analyzing Money Flow Index and other technical indicators
All  Next Launch Module

Galapagos Upcoming and Recent Events

Galapagos Company Earnings Announcements Dates

Upcoming Quarterly Earning Report (could be delayed)February 20, 2020
Next Earnings ReportApril 24, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 20, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Galapagos Corporate Filings

Galapagos SEC Reporting

Unclassified Corporate Event

Galapagos Corporate Directors

Katrine Bosley Independent Non-Executive Director
Howard Rowe Non-Executive Independent Director
Harrold Barlingen Non-Executive Director
Please check Risk vs Return Analysis. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Company logos by clearbit